
InflaRx (IFRX) Stock Forecast & Price Target
InflaRx (IFRX) Analyst Ratings
Bulls say
InflaRx is strategically leveraging its advanced pipeline, strong clinical data, and differentiated C5aR inhibition technology to pursue multiple opportunities in autoimmune and inflammatory diseases. Recent news of a pipeline shift, increased cash position, and plans to assertively pursue development of izicopan in ANCA vasculitis signal strong potential for the stock. In addition to its potential in ANCA vasculitis, izicopan shows promise in addressing high unmet needs in other indications such as AAV, IgAN, FSGS, and more, and could generate significant value through M&A activities.
Bears say
InflaRx is currently conducting Phase 2 trials for their product candidate izicopan targeting various inflammatory renal diseases, but there may be potential challenges and toxicity signals associated with C5a/C5aR inhibition. The company is also planning for potential approval and considering a single Phase 2/3 trial to conserve resources. However, their current cash position is expected to provide runway through 2029 and they have potential for a differentiated offering in the AAV market.
This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.
InflaRx (IFRX) Analyst Forecast & Price Prediction
Start investing in InflaRx (IFRX)
Order type
Buy in
Order amount
Est. shares
0 shares